GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CollPlant Biotechnologies Ltd (FRA:CPT) » Definitions » Degree of Operating Leverage

CollPlant Biotechnologies (FRA:CPT) Degree of Operating Leverage : -1.68 (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is CollPlant Biotechnologies Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. CollPlant Biotechnologies's Degree of Operating Leverage for the quarter that ended in Sep. 2024 was -1.68. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for CollPlant Biotechnologies's Degree of Operating Leverage or its related term are showing as below:

FRA:CPT's Degree of Operating Leverage is ranked better than
78.29% of 903 companies
in the Biotechnology industry
Industry Median: -0.01 vs FRA:CPT: -1.68

CollPlant Biotechnologies Degree of Operating Leverage Historical Data

The historical data trend for CollPlant Biotechnologies's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CollPlant Biotechnologies Degree of Operating Leverage Chart

CollPlant Biotechnologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Degree of Operating Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.44 -0.12 -0.65 269.18 -0.02

CollPlant Biotechnologies Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.02 -0.03 -1.75 -1.68

Competitive Comparison of CollPlant Biotechnologies's Degree of Operating Leverage

For the Biotechnology subindustry, CollPlant Biotechnologies's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CollPlant Biotechnologies's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where CollPlant Biotechnologies's Degree of Operating Leverage falls into.



CollPlant Biotechnologies Degree of Operating Leverage Calculation

CollPlant Biotechnologies's Degree of Operating Leverage for the quarter that ended in Sep. 2024 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -16.815 (Sep. 2024) / -6.773 (Sep. 2023) - 1 )/( 0.599 (Sep. 2024) / 9.899 (Sep. 2023) - 1 )
=1.4827/-0.9395
=-1.58***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


CollPlant Biotechnologies  (FRA:CPT) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


CollPlant Biotechnologies Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of CollPlant Biotechnologies's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


CollPlant Biotechnologies Business Description

Traded in Other Exchanges
Address
4 Oppenheimer Street, P.O. Box 4132, Weizmann Science Park, Rehovot, ISR, 7670104
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.